RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for pancreatic cancer: study tests Cutting-Edge therapies
Disease control TerminatedThis study aimed to test new treatments for people with pancreatic cancer that hasn't spread. It was designed for three groups: those whose tumors can be removed by surgery, those where it's borderline, and those with advanced local disease. The goal was to see if new therapies w…
Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:50 UTC
-
New combo therapy aims to control hard-to-treat pancreatic cancer
Disease control TerminatedThis early-phase study tests a drug called NBTXR3, which is activated by radiation, in people with pancreatic cancer that is locally advanced or borderline resectable. The goal is to find a safe dose and see if it helps control the disease. About 24 adults will take part, and the…
Matched conditions: RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 05:37 UTC